NewLink Genetics (NLNK) IPO Trades Higher
Tweet
Share
E-mailGet Alerts NLNK Hot Sheet
Join SI Premium – FREE
The IPO for NewLink Genetics Corporation (Nasdaq: NLNK) is open for trading. Shares are trading at $7.29 after pricing 6,200,000 shares a $7, which was below the expected $10-$12 range.
Stifel Nicolaus Weisel and Canaccord Genuity Inc. are acting as joint book-running managers for the offering, and Robert W. Baird & Co. Incorporated and Cantor Fitzgerald & Co. are acting as co-managers for the offering.
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians.
Stifel Nicolaus Weisel and Canaccord Genuity Inc. are acting as joint book-running managers for the offering, and Robert W. Baird & Co. Incorporated and Cantor Fitzgerald & Co. are acting as co-managers for the offering.
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Upgrades Papa John's (PZZA) to Hold, 'near-term expectations are reasonable'
- Block Inc. (SQ) PT Raised to $98 at Baird
- Tungray Technologies (TRSG) Closes $5M IPO
Create E-mail Alert Related Categories
IPOsRelated Entities
Stifel, Cantor Fitzgerald, Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
